Point72 Asset Management
VRTX icon

Point72 Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Point72 Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.61M Sell
3,600
-3,500
-49% -$1.63M ﹤0.01% 2454
2025
Q4 		$3.22M Buy
+7,100
New +$3.06M ﹤0.01% 2153
2025
Q1 		– Sell
-20,000
Closed -$8.05M – 2577
2024
Q4 		$8.05M Buy
+20,000
New +$9.27M 0.02% 769

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Point72 Asset Management's VRTX Position: Q4 2023 in Review

Point72 Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 85,414 shares — an estimated $29.7M sold.

Point72 Asset Management first reported a position in VRTX in Q2 2014 and held it in 29 quarters. The position peaked at $143M in Q1 2021. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Point72 Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 85,414 Vertex Pharmaceuticals shares in Q4 2023, an estimated $29.7M.
  • Point72 Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 29 quarters.
  • Point72 Asset Management's Vertex Pharmaceuticals position peaked at $143M in Q1 2021.
  • 1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.